Transdermal ketamine - Silo Pharma/Zylo Therapeutics
Alternative Names: SP-26; SP-26 ketamine-loaded implantLatest Information Update: 28 May 2025
At a glance
- Originator Silo Pharma; Zylo Therapeutics
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fibromyalgia; Pain
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Fibromyalgia in USA (Transdermal, Implant)
- 30 Apr 2025 Pharmacodynamics data from preclinical trials in Fibromyalgia released by Silo Pharma
- 25 Apr 2025 Preclinical trials in Fibromyalgia in USA (SC) , before April 2025